Asianet NewsableAsianet Newsable

Novavax claims 90.4% efficacy against Covid-19, SII to manufacture it as Covavax

Novavax, which is reported to be 90.4% effective against Coronavirus, will be manufactured in India as Covovax by the Serum Institute of India and it is estimated that the vaccine shots will be available by September this year.

Novavax claims 90.4% efficacy against Covid-19, SII to manufacture it as Covavax-VPN
Author
New Delhi, First Published Jun 15, 2021, 8:58 AM IST

Novavax, which is reported to be 90.4% effective against Coronavirus, will be manufactured in India as Covovax by the Serum Institute of India. It is estimated that the vaccine shots will be available by September this year.

Novavax is currently undergoing Phase 2/3 bridging trials. The SII has enrolled 1600 volunteers aged above 18 across 15 centres to conduct the test.

What is Novavax?

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2. 

According to the company, NVX-CoV2373 was created using recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein. The vaccine is formulated with a saponin-based Matrix-M adjuvant to stimulate high levels of neutralizing antibodies and enhance the immune response. 

NVX-CoV2373 has purified protein antigen and can neither replicate nor can it cause Covid-19. 

How does it work?

The American biotechnology company claims that NVX-CoV2373 induces antibodies that block the binding of spike protein to cellular receptors and provides protection from infection and disease. 

It also claims to boost immunity by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.

How effective is the vaccine?

Novavax or NVX-CoV2373 is a recombinant nanoparticle protein-based vaccine. 

According to the latest Phase 3 data released by the company, the vaccine demonstrated 100% protection against moderate and severe disease. 

The trials, which were conducted in the United States and Mexico, showed an overall efficacy of 90.4%.

What are the storage requirements?

NVX-CoV2373 can be stored and stable at 2-8 degree Centigrade. It is packaged in 10-dose vials.

Follow Us:
Download App:
  • android
  • ios